Humasis Co

Humasis Co Current Liabilities

The Current Liabilities of Humasis Co (205470.KQ) as of Nov 9, 2026 is 405.30 M KRW. In the previous year, Current Liabilities was 21.72 B KRW — a change of -98.13% (lower).

Current Liabilities

405.30 MKRW

YoY

-98.13%

Last updated:

Current Liabilities of Humasis Co is 2025 405.30 M KRW. Current Liabilities of Humasis Co was 2024 21.72 B KRW. It decreases by -98.13% lower compared to the previous year.

The Humasis Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
3.38 B KRW
Jan 1, 2019
15.47 B KRW
Jan 1, 2020
9.66 B KRW
Jan 1, 2021
40.59 B KRW
Jan 1, 2022
18.01 B KRW
Jan 1, 2023
8.32 B KRW
Jan 1, 2024
21.72 B KRW
Jan 1, 2025
405.30 M KRW
The Humasis Co Current Liabilities history
YEARCurrent LiabilitiesYoY
405.30 MKRW-98.13%
21.72 BKRW+161.10%
8.32 BKRW-53.80%
18.01 BKRW-55.63%
40.59 BKRW+320.04%
9.66 BKRW-37.55%
15.47 BKRW+357.36%
3.38 BKRW-13.26%
3.90 BKRW—
0.00KRW-100.00%
4.23 BKRW+1.78%
4.16 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Current Liabilities of Humasis Co is 405.30 M KRW in 2025.

Current Liabilities of Humasis Co changed from 21.72 B KRW to 405.30 M KRW, representing a -98.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humasis Co

All Key Metrics — Humasis Co